Mixed tocotrienols show promise against prostate cancer

RESEARCHERS at Rutgers University in New Jersey, USA, studied the anticancer properties of d-mixed tocotrienol complex towards prostate cancer in the transgenic adenocarcinoma mouse prostate (TRAMP) mouse model. After observing TRAMP mice in the positive control group and normal (wild-type) non-transgenic mice fed a regular diet for 16 weeks and a supplemented group of TRAMP mice fed 0.1%, 0.3% or 1% Tocomin from Carotech Inc for 16 weeks, the researchers conclude in their study published in Nutrition and Cancer (August 2010) that Tocomin effectively suppresses overall tumour formation. "This study further supports the potential use of Tocomin?full spectrum tocotrienol complex as a prostate cancer chemopreventive agent in human," says WH Leong, vice president, Carotech Inc. Prostate cancer is the second most common male cancer in most developed nations, with close to one million men diagnosed with prostate cancer worldwide in 2008.Zoom Lebron XIII 13